PENUMBRA INC (PEN) Stock Price, Quote, News and Overview
NYSE:PEN - New York Stock Exchange, Inc. - US70975L1070 - Common Stock
PEN Quote and Key Statistics
PENUMBRA INC
NYSE:PEN (1/21/2025, 8:20:03 PM)
Premarket: 267.4 -0.8 (-0.3%)268.2
+4.51 (+1.71%)
PEN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.97% | ||
| ROA | 2.34% | ||
| ROE | 3.13% | ||
| Debt/Equity | 0.02 |
PEN Performance and Technical Analysis
PEN Ownership and Analysts
PEN Latest News and Analysis
Top movers in Monday's after hours session
Which stocks are moving after the closing bell on Monday?
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025
/PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full...
Inspire Medical's Sleep Innovations Driving Big Gains
Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81.
Noteworthy Tuesday Option Activity: SQ, DKS, PEN
About PEN
Company Profile
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. The company is headquartered in Alameda, California and currently employs 4,200 full-time employees. The company went IPO on 2015-09-18. The firm designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. The company is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. The company is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Company Info
PENUMBRA INC
One Penumbra Place
Alameda CALIFORNIA 94502 US
CEO: Adam Elsesser
Employees: 4200
Company Website: https://www.penumbrainc.com/
Investor Relations: https://www.penumbrainc.com/investors/
Phone: 15107483200
PEN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 89.9 | 215.18B | ||
| ABT | ABBOTT LABORATORIES | 25.84 | 202.57B | ||
| SYK | STRYKER CORP | 34.01 | 150.91B | ||
| BSX | BOSTON SCIENTIFIC CORP | 42.76 | 148.72B | ||
| MDT | MEDTRONIC PLC | 16.83 | 113.33B | ||
| BDX | BECTON DICKINSON AND CO | 18.27 | 69.71B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.21 | 41.27B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.7 | 39.90B | ||
| RMD | RESMED INC | 29.89 | 36.38B | ||
| IDXX | IDEXX LABORATORIES INC | 39.03 | 34.99B | ||
| DXCM | DEXCOM INC | 50.78 | 33.72B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 19.98 | 24.97B |